Add BrightSurf on Google Email

Delaying prostate cancer radiation therapy offers room for flexibility in pandemic peak

A new study by Brigham and Women's Hospital found that delaying radiation therapy for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, is unlikely to impact survival. This flexibility in radiation timing could help patients minimize exposure to COVID-19 by s...

SourceBrigham and Women's Hospital·JournalJAMA Oncology·DateAug 13, 2020

Genomic signature explains FDG-avidity of PSMA-suppressed prostate tumors

A genomic signature associates with differential expression of glucose transporters and hexokinase proteins in prostate cancers with low PSMA expression. This allows for improved uptake of 18F-FDG compared to PSMA-targeted radioligands, making it an attractive imaging tool for neuroendocrine prostate cancer patients.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 22, 2020

New theranostic agents show efficacy in prostate cancer treatment in preclinical studies

Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 13, 2020

Largest study of prostate cancer genomics in Black Americans ids targets for therapies

A new study has identified genes more frequently altered in prostate tumors from men of African ancestry compared to other racial groups. The research found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, but suggests that precision medicine approaches can be effective if...

SourceUniversity of California - San Francisco·JournalClinical Cancer Research·DateJul 10, 2020

Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation

A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalScience Translational Medicine·DateApr 1, 2020

Exercise works for those beginning cancer treatment

A study led by James Cook University found that supervised exercise sessions can reduce the negative side effects of Androgen Deprivation Therapy (ADT) in prostate cancer patients. The research showed sustained benefits in cardiovascular risk profile and quality of life, but not in cardiopulmonary fitness and fatigue.

SourceJames Cook University·JournalBritish Journal of Urology·DateMar 11, 2020

New computational tools identify alternative splicing changes in aggressive cancers

A new study identifies a strong cancer driver gene linked to alternative splicing changes in aggressive cancers. The researchers developed computational tools and biological model systems to analyze RNA sequences from nearly 900 prostate tissue samples, revealing over 13,000 alternative splicing events.

SourceChildren's Hospital of Philadelphia·JournalProceedings of the National Academy of Sciences·DateFeb 17, 2020